Not yet filed. No Q3 2026 Form 13F from Perceptive Advisors has been detected on SEC EDGAR yet. The deadline for the quarter ended Sep 30, 2026 is Monday, Nov 16, 2026.
From the fund's 2026 Q2 Form 13F (filed Aug 14, 2026) — the latest quarter fully processed on this site.
| Stock | Shares | Portfolio weight |
|---|---|---|
| PRAX · Praxis Precision Medicines, Inc. | 2,035,986 | 10.23% |
| SYRE · SPYRE THERAPEUTICS INC | 4,319,496 | 5.76% |
| CELC · Celcuity Inc. | 3,197,200 | 5.02% |
| ASND · Ascendis Pharma A/S | 1,163,721 | 4.66% |
| RYTM · RHYTHM PHARMACEUTICALS INC | 2,586,295 | 4.31% |
| ROIV · Roivant Sciences Ltd. | 8,085,461 | 4.30% |
| RLAY · Relay Therapeutics, Inc. | 14,106,187 | 3.96% |
| TVTX · Travere Therapeutics, Inc. | 3,752,574 | 3.20% |
| KARD · KARDIGAN INC | 8,200,662 | 2.94% |
| EWTX · Edgewise Therapeutics, Inc. | 4,373,974 | 2.67% |
Largest increase 2026 Q1 → 2026 Q2: ADPT (+698.2% of shares). New position in 2026 Q2: ASND (4.66% of the portfolio). Largest trim 2026 Q1 → 2026 Q2: GH (-86.2% of shares). Exited in 2026 Q2: EVMN, IKT, NMRA and 7 more.
Full record: Perceptive Advisors fund page · manager profile & 13F-clone record · Q3 2026 season tracker.
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.